Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.03 Insider Own2.50% Shs Outstand105.89M Perf Week3.76%
Market Cap1.17B Forward P/E- EPS next Y-0.97 Insider Trans30.33% Shs Float92.77M Perf Month26.61%
Income-106.70M PEG- EPS next Q-0.19 Inst Own51.50% Short Float19.23% Perf Quarter53.97%
Sales76.70M P/S15.24 EPS this Y-3.10% Inst Trans-3.60% Short Ratio7.40 Perf Half Y63.07%
Book/sh-0.95 P/B- EPS next Y-10.20% ROA-63.10% Target Price13.83 Perf Year124.39%
Cash/sh1.45 P/C7.61 EPS next 5Y5.60% ROE148.90% 52W Range4.13 - 10.98 Perf YTD107.13%
Dividend- P/FCF- EPS past 5Y-20.00% ROI-176.90% 52W High0.55% Beta-
Dividend %- Quick Ratio1.30 Sales past 5Y160.30% Gross Margin- 52W Low167.31% ATR0.62
Employees254 Current Ratio1.30 Sales Q/Q305.80% Oper. Margin- RSI (14)68.13 Volatility7.82% 6.27%
OptionableYes Debt/Eq- EPS Q/Q30.80% Profit Margin- Rel Volume1.80 Prev Close10.42
ShortableYes LT Debt/Eq- EarningsNov 10 AMC Payout- Avg Volume2.41M Price11.04
Recom1.60 SMA2014.03% SMA5021.77% SMA20053.50% Volume4,336,413 Change5.95%
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Dec-17-14 08:16AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:00AM  Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors GlobeNewswire
Dec-12-14 08:00AM  Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium GlobeNewswire
Dec-04-14 08:00AM  Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research GlobeNewswire
Dec-01-14 04:01PM  Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day and Present Research on Multiple Molecules in December 2014 GlobeNewswire
Nov-25-14 11:15AM  Insider Trading Alert - FCS, GDOT And MACK Traded By Insiders at TheStreet
Nov-21-14 08:00AM  Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics GlobeNewswire
Nov-20-14 04:20PM  Merrimack Pharmaceuticals' MM-398 Gets Fast Track Status Zacks
Nov-19-14 04:30PM  The S&P failed to extend its 4-day winning streak following headlines out of the Fed Yahoo Finance Blogs
01:04PM  MERRIMACK PHARMACEUTICALS INC Financials EDGAR Online Financials
12:34PM  Insider Trading Alert - MACK, GWRE And CCOI Traded By Insiders at TheStreet
08:00AM  Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer GlobeNewswire
Nov-18-14 06:00AM  'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen at TheStreet
Nov-17-14 09:09AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:30AM  Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors GlobeNewswire
Nov-14-14 12:49PM  Insider Trading Alert - TASR, SAVE And MACK Traded By Insiders at TheStreet
Nov-13-14 08:00AM  Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 EORTC-NCI-AACR Symposium GlobeNewswire
08:00AM  Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference GlobeNewswire
Nov-10-14 06:57PM  Merrimack posts 3Q loss AP
04:17PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
04:01PM  Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results GlobeNewswire
07:07AM  Q3 2014 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close CCBN
Nov-07-14 03:35PM  Will Inovio (INO) Disappoint Expectations for Q3 Earnings? Zacks
03:30PM  Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? Zacks
Nov-06-14 03:02PM  Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? Zacks +5.03%
08:30AM  Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer GlobeNewswire
Nov-05-14 09:00AM  FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer GlobeNewswire -5.76%
05:49AM  Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? Zacks
Nov-03-14 08:00AM  Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call GlobeNewswire
02:23AM  Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% Zacks
Oct-31-14 03:11AM  Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% Zacks
03:07AM  Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% Zacks
Oct-30-14 03:19AM  ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% Zacks
Oct-27-14 08:08AM  Merrimack Pharmaceuticals (MACK) Shares March Higher, Can It Continue? Zacks
02:15AM  Verastem (VSTM) Shows Strength: Stock Adds 7% in Session Zacks
02:12AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% Zacks
Oct-24-14 04:25PM  Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case Zacks
06:47AM  Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% Zacks
06:35AM  Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% Zacks
Oct-22-14 06:43AM  Illumina (ILMN) Looks Strong: Stock Gains 9.2% Zacks
Oct-21-14 02:38AM  Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session Zacks
02:35AM  NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% Zacks
Oct-20-14 04:24AM  Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% Zacks
Oct-17-14 02:04AM  Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% Zacks
Oct-16-14 06:23AM  Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% Zacks +6.11%
06:20AM  Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Zacks
Oct-15-14 02:10AM  MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% Zacks
Oct-13-14 06:37AM  Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% Zacks
Oct-10-14 06:47AM  Why Merrimack (MACK) Could Be Positioned for a Surge? Zacks
Oct-07-14 04:01PM  Get Ready To Be Surprised This Earnings Season Zacks -5.19%
Oct-06-14 02:28PM  Top 5 Biotech Stocks Over The Past Year Benzinga
Sep-30-14 08:00AM  Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer GlobeNewswire
Sep-29-14 07:15AM  How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry Zacks
Sep-26-14 09:12AM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
09:10AM  Will Merrimack (MACK) Continue to Surge Higher? Zacks
07:37AM  Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session Zacks
Sep-25-14 04:24PM  Skechers and Apple are big market movers AP +7.37%
12:10PM  Baxter and Merrimack Collaborate on Drug Development Zacks
Sep-24-14 11:42AM  Midday movers: Hasbro, KB Home, Transocean & more at CNBC
10:30AM  Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today at TheStreet
10:14AM  Merrimack, Baxter to collaborate on cancer drug AP
09:51AM  US STOCKS-Wall St climbs after three-day slump; housing data on tap Reuters
08:21AM  US STOCKS-Bed, Bath & Beyond, Merrimack Pharma surge in premarket Reuters
08:14AM  Merrimack Does Well to License Marginal Cancer Drug to Baxter at TheStreet
08:08AM  Baxter to market Merrimack's cancer drug outside U.S. Reuters
07:53AM  Merrimack Pharma shares surge on licensing pact with Baxter at MarketWatch
07:43AM  [$$] Baxter, Merrimack to Collaborate on Pancreatic Cancer Drug at The Wall Street Journal
07:15AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materi EDGAR Online
07:00AM  Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 Business Wire
Sep-20-14 09:10AM  10 Stocks Trading Under $10 With Huge Upside Potential at 24/7 Wall St.
Sep-19-14 08:00AM  Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress GlobeNewswire
Sep-12-14 08:59AM  5 Stocks Under $10 Soaring Higher at TheStreet
Sep-10-14 06:41AM  Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? Zacks
Sep-09-14 06:42AM  Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? Zacks
Sep-08-14 02:25PM  3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus Benzinga
Aug-28-14 06:58AM  Is Merrimack Pharmaceuticals (MACK) Stock a Solid Choice Right Now? Zacks
Aug-11-14 07:18AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
07:07AM  Q2 2014 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
07:05AM  Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval GlobeNewswire
07:00AM  Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results GlobeNewswire
Aug-07-14 08:20AM  4 Biotech Stocks Where Analysts See 100% Upside, or Even Higher at 24/7 Wall St. +5.03%
Aug-04-14 04:01PM  Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call GlobeNewswire
Jul-08-14 11:17AM  Is Now The Time To Buy Merrimack Pharmaceuticals? at Seeking Alpha
Jul-03-14 10:36AM  4 Biotech Stocks Worth A Look Ahead Of FDA Approvals Benzinga
Jun-30-14 11:37AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online
Jun-28-14 09:21AM  Key Stocks With Insider Buying This Week at 24/7 Wall St.
Jun-25-14 04:05PM  Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer GlobeNewswire
12:53PM  5 Stocks With Big Insider Buying at TheStreet
Jun-24-14 08:04PM  Why Micron Technology, Qihoo 360, and Merrimack Pharmaceuticals Rose Today at Motley Fool +5.76%
Jun-23-14 03:45PM  Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights Zacks
02:55PM  Nasdaq stocks posting largest percentage decreases
07:45AM  Merrimack Pharmaceuticals (MACK) Crumbles: Stock Tanks by 11.3% Zacks
Jun-22-14 10:17AM  2 Top Catalysts This Week: AstraZeneca and Merrimack at Motley Fool
Jun-20-14 08:34PM  Why Hercules Offshore, Merrimack Pharmaceuticals, and Smith & Wesson Holdings Tumbled Today at Motley Fool -11.28%
11:38AM  Merrimack Pharmaceuticals: The Sleeping Giant Of Cancer Care at Seeking Alpha
11:34AM  Midday movers: Alstom, CarMax, Sprint & More at CNBC
09:08AM  Today's Top Biotech Stocks to Watch: AbbVie, Merrimack Pharmaceuticals, and Shire plc at Motley Fool
Jun-19-14 07:52PM  Why Merrimack Pharmaceuticals Inc. Shares Plunged in After Hours at Motley Fool
04:47PM  Why Merrimack Pharmaceuticals (MACK) Stock is Down in After-Hours Trading Today at TheStreet
04:29PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for the treatment of various cancers; MM-121, a human monoclonal antibody that targets the ErbB3 cell surface receptor, which is in multiple ongoing Phase I and Phase II clinical trials to inhibit cancer growth directly; and MM-111, a bispecific antibody that is in multiple ongoing Phase I and Phase II clinical trials to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor. The company's product candidates also include MM-302, an antibody drug conjugated liposomal doxorubicin that is in Phase I clinical trials for advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trials for refractory solid tumors; and MM-141, a human tetravalent bispecific antibody that is in Phase I clinical trials to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3. Its therapeutic oncology product candidates are used in the treatment of various cancers, including pancreatic, colorectal, gastric, glioma, ovarian, breast, lung, and other gynecological cancers. The company has collaboration and license agreements with Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, University of California, U.S. Public Health Service, and Selexis SA. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Edward J.SVP & Pres, Healthcare SolDec 15Option Exercise1.766,00010,56027,385Dec 16 04:51 PM
Stewart Edward J.SVP & Pres, Healthcare SolDec 15Sale10.636,00063,78021,385Dec 16 04:51 PM
Mulroy Robert J.President and CEODec 08Option Exercise1.42118,247167,7021,339,316Dec 09 05:14 PM
Mulroy Robert J.President and CEODec 08Sale9.7325,000243,2501,270,232Dec 09 05:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolDec 05Option Exercise1.713,0005,13024,385Dec 09 05:19 PM
Mulroy Robert J.President and CEODec 05Option Exercise1.25175,000218,7501,421,069Dec 09 05:14 PM
Mulroy Robert J.President and CEODec 05Sale9.85175,0001,723,7501,246,069Dec 09 05:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolDec 05Sale10.003,00030,00021,385Dec 09 05:19 PM
PORTER MICHAEL EDirectorDec 02Buy8.718,00069,680633,164Dec 04 12:14 PM
PORTER MICHAEL EDirectorNov 21Buy9.005,67551,075625,164Nov 24 04:40 PM
PORTER MICHAEL EDirectorNov 20Buy8.766,23454,610619,489Nov 24 04:40 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 18Option Exercise1.711,0001,71022,385Nov 18 05:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 18Sale9.001,0009,00021,385Nov 18 05:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 17Option Exercise1.714,0006,84025,385Nov 18 05:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 17Sale8.444,00033,76021,385Nov 18 05:07 PM
PORTER MICHAEL EDirectorNov 14Buy8.295,00041,450613,255Nov 18 05:08 PM
CROCKER GARY LDirectorNov 13Buy8.378,63072,2332,858,961Nov 14 10:11 AM
CROCKER GARY LDirectorNov 12Buy8.625,76049,6512,850,331Nov 14 10:11 AM
Stewart Edward J.SVP & Pres, Healthcare SolOct 23Option Exercise1.713,0005,13024,385Oct 24 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolOct 23Sale9.053,00027,15021,385Oct 24 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolOct 15Option Exercise1.714,0006,84025,385Oct 17 04:44 PM
Stewart Edward J.SVP & Pres, Healthcare SolOct 15Sale8.004,00032,00021,385Oct 17 04:44 PM
Sullivan William A.CFO and TreasurerSep 30Option Exercise2.6940,878109,96251,878Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 30Sale8.9440,878365,44911,000Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 29Option Exercise2.1264,404136,53675,404Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 29Sale8.4064,404540,99411,000Oct 01 05:04 PM
Stewart Edward J.SVP & Pres, Healthcare SolSep 24Option Exercise1.7112,00020,52033,385Sep 26 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolSep 24Sale8.2212,00098,64021,385Sep 26 04:14 PM
Mulroy Robert J.President and CEOAug 29Option Exercise1.2519,83224,7901,246,069Sep 02 10:45 AM
Nielsen Ulrik B.SVP and CSOAug 26Option Exercise1.2550,00062,500226,811Aug 28 04:25 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Option Exercise1.2524,00030,00045,385Aug 28 04:23 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Sale6.8724,000164,88021,385Aug 28 04:23 PM
Sinskey Anthony JDirectorAug 25Option Exercise1.2525,00031,250422,543Aug 27 08:22 AM
Mulroy Robert J.President and CEOAug 21Option Exercise1.25280,168350,2101,226,237Aug 25 10:04 AM
PORTER MICHAEL EDirectorJun 23Buy6.8432,390221,548568,255Jun 24 09:16 AM
CROCKER GARY LDirectorJun 23Buy6.8436,000246,2402,844,571Jun 24 09:15 AM
Dresser James van B.DirectorJun 02Option Exercise1.2525,00031,250168,974Jun 03 01:26 PM
Stewart Edward J.SVP & Pres, Healthcare SolMay 27Option Exercise1.2516,00020,00037,385May 29 07:17 PM
Nielsen Ulrik B.SVP and CSOMay 27Option Exercise1.27105,000133,550281,811May 29 07:18 PM
Stewart Edward J.SVP & Pres, Healthcare SolMay 27Sale8.0016,000128,00021,385May 29 07:17 PM
Nielsen Ulrik B.SVP and CSOMay 27Sale8.01105,000841,050176,811May 29 07:18 PM
CROCKER GARY LDirectorMay 20Buy6.694,00026,7602,808,571May 22 11:43 AM
Quigley James H.DirectorMay 19Buy6.585,00032,90056,500May 21 07:57 AM
CROCKER GARY LDirectorMay 19Buy6.716,00040,2602,804,571May 20 09:53 AM
CROCKER GARY LDirectorMay 16Buy6.633,40022,5422,798,571May 20 09:53 AM
PORTER MICHAEL EDirectorMay 16Buy6.505,00032,500535,865May 16 02:26 PM
PORTER MICHAEL EDirectorMay 14Buy6.4910,00064,900530,865May 16 02:26 PM
Sinskey Anthony JDirectorMay 13Buy6.745,00033,700397,543May 15 08:18 AM
Fehr Gordon J.DirectorMay 12Option Exercise1.2525,00031,250215,143May 14 02:28 PM
PORTER MICHAEL EDirectorMay 08Option Exercise1.9420,00038,700515,865May 09 01:15 PM
PORTER MICHAEL EDirectorMay 08Buy6.485,00032,400520,865May 09 01:15 PM
PORTER MICHAEL EDirectorMay 07Buy6.705,00033,500495,865May 09 01:15 PM
Nash Sarah EDirectorMay 07Buy6.7915,000101,850955,296May 09 10:57 AM
CROCKER GARY LDirectorMay 07Buy6.774,40029,7882,795,171May 08 10:44 AM
CROCKER GARY LDirectorMay 06Buy6.857,50051,3752,790,771May 07 01:19 PM
CROCKER GARY LDirectorMay 05Option Exercise1.2535,00043,7502,773,271May 06 10:08 AM
CROCKER GARY LDirectorMay 05Buy6.6910,00066,9002,738,271May 06 10:08 AM
PORTER MICHAEL EDirectorMay 05Buy6.4115,00096,150485,865May 05 01:21 PM
PORTER MICHAEL EDirectorMay 05Buy6.125,00030,600490,865May 07 03:02 PM
CROCKER GARY LDirectorMay 05Buy6.9210,00069,2002,783,271May 07 01:19 PM
CROCKER GARY LDirectorMar 12Option Exercise1.2550,00062,5002,728,271Mar 14 08:56 AM